AllCells understands the complexities of biomedical research. Following stringent protocols is paramount, and staying up to date on scientific discoveries is a principle endeavor. To ensure the quality, viability, and purity of AllCells’ products, the links below are dedicated to providing AllCells’ clients with technical protocols and educational resources to optimize their experiments.

Storage & Thawing Protocol


To ensure the quality, viability, and purity of our products, AllCells adheres to a consistent method for cell storage and thawing. By strictly following an in-depth, step-by-step protocol, AllCells’ clients can depend on reliable results. Continue reading for additional precautions and safety advisories.

LEARN MORE

Counting Protocol


To determine the number of viable cells in a given sample, researchers need to utilize a proven protocol for precisely counting their cells. AllCells has developed a protocol that is based on scientifically-proven techniques and methods for counting cells.

LEARN MORE

Shipping Network Map

Shipping & Delivery Options


Product integrity, delivery speed, and optimized pickup times – AllCells’ shipping principles. To deliver on these principles, AllCells utilizes an industry-leading AeroSafe Global Shipping Package, customer-focused delivery options, and an optimized processing schedule. You can trust AllCells to deliver the highest quality cells on time and on your schedule.

READ MORE

Publications


Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII

Alexander Sternjak, Fei Lee, Oliver Thomas, Mercedesz Balazs, Joachim Wahl

AMG 596 is a bispecific T-cell engager (BiTE) immuno-oncology therapy in clinical development for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with limited therapeutic options. AMG 596 is composed of two single-chain variable fragments that simultaneously bind to the tumor-specific antigen, EGFR variant III (EGFRvIII), on GBM cells and to CD3 on T cells...

READ MORE

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

Claire L. Langrish, J. Michael Bradshaw, Michelle R. Francesco, Timothy D. Owens

Bruton tyrosine kinase (BTK) is expressed in B cells and innate immune cells, acting as an essential signaling element in multiple immune cell pathways. Selective BTK inhibition has the potential to target multiple immune-mediated disease pathways. Rilzabrutinib is an oral, reversible, covalent BTK inhibitor designed for immune-mediated diseases. We examined the pharmacodynamic profile of rilzabrutinib and its preclinical...

READ MORE